Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003396 · ClinicalTrials.gov registry record · Phase 2
Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer
A Phase 2 study, sponsored by University of Maryland, Baltimore.
- Completed
- Registry status
- Phase 2
- Development phase
- 42
- Enrollment target
NCT00003396 is a Phase 2 study that has completed, run by University of Maryland, Baltimore. The registered enrollment target is 42 participants.
The verdict
NCT00003396, a Phase 2 study, has completed, sponsored by University of Maryland, Baltimore.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 42 participants
- Enrollment target
Study Summary
RATIONALE: Peripheral stem cell transplantation may be able to replace immune cells that were destroyed by chemotherapy or radiation therapy used to kill tumor cells. PURPOSE: Phase II trial to study the effectiveness of peripheral stem cell transplantation from related donors to prevent graft-versus-host disease in treating patients with hematologic cancer.
Interventions
- DRUG cyclophosphamide
- DRUG melphalan
- PROCEDURE peripheral blood stem cell transplantation
- BIOLOGICAL anti-thymocyte globulin
- BIOLOGICAL graft-versus-tumor induction therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 1998-09 |
| Est. Completion | 2002-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00003396
The ClinicalTrials.gov registry entry for NCT00003396 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Maryland, Baltimore, which has 560 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which cyclophosphamide is the first listed.
NCT00003396 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00003396 about?
NCT00003396 is a clinical study titled "Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer". RATIONALE: Peripheral stem cell transplantation may be able to replace immune cells that were destroyed by chemotherapy or radiation therapy used to kill tumor cells. PURPOSE: Phase II trial to study the effectiveness of peripheral stem cell transplantation from related donors to prevent graft-vers...
What is the current status of trial NCT00003396?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 42 participants. The study started on 1998-09. Estimated completion is 2002-12.
What interventions are being tested in trial NCT00003396?
The interventions under investigation include: cyclophosphamide (DRUG), melphalan (DRUG), peripheral blood stem cell transplantation (PROCEDURE), anti-thymocyte globulin (BIOLOGICAL), graft-versus-tumor induction therapy (BIOLOGICAL).
Who is sponsoring clinical trial NCT00003396?
This trial is sponsored by University of Maryland, Baltimore, which has 560 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.